Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06972147
Recruiting Observational

Prevalence and Description of FIRE (Food Induced Immediate Response of the Esophagus) in the Pediatric Population With Eosinophilic Esophagitis

NCT06972147 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Angers
Phase
Observational
Started
2025-07-01
Last updated
2026-06-15

Condition(s) studied

Eosinophilic Esophagitis

Study summary

A new clinical entity of eosinophilic esophagitis, Food Induced Immediate Response of the Esophagus or FIRE, has been described since 2020. Diagnostic criteria are not clearly established. Specific questioning is necessary for differential diagnosis, such as the oro-pharyngeal syndrome notably described in pollinics, or a mechanical blockage strictly speaking linked to esophagitis. The aim is to obtain epidemiological data on this entity.

Eligibility

Sex
ALL
Min age
6 Years
Max age
17 Years
Healthy volunteers
No
Inclusion Criteria: * Patients over 6 and under 18 years of age at the time of inclusion * Follow-up in the allergology unit of Angers University Hospital for eosinophilic esophagitis Exclusion Criteria: * Patients or legal representative with severe communication or language comprehension difficulties * Patients or legal representatives objecting to study participation

Primary outcome measure(s)

  • diagnosis of FIRE syndrome — day 1
    symptoms such as pain, pressure, choking or narrowing, in the oesophagus or retrosternum, within 10 minutes of ingestion, lasting a maximum of 120 minutes, when a specific food is ingested

Trial sites (2)

FacilityCityRegionStatus
HOPPE Anne Angers France Recruiting
CHU Lille Lille France Not Yet Recruiting

More University Hospital, Angers trials in France

Postoperative Analgesia Using a Perineural Catheter Versus a Single Nerve Block in Rearfoot Surgery Recruiting
Impact of Prevention of Safe Sleeping and Unexpected Infant Death Starting soon
Assessment of the Mental State of Parents of Premature Children and Impact on Neurodevelopment of the Child Active, not recruiting
Human Seminal Plasma Allergy: Quality of Life Starting soon
AttachMent Preterm in the Loire Infant Follow-up Team Recruiting

Other trials for the same condition

EDN and Eosinophilic Esophagitis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06972147 on ClinicalTrials.gov ↗ ← All trials in France